For decades, the management of cardiovascular risk has rested heavily on a single pharmacological pillar — the statin. Now, researchers at the University of Barcelona have engineered short DNA molecules capable of silencing the gene behind PCSK9, a protein that undermines the body's own cholesterol-clearing machinery, achieving a 47% reduction in cholesterol with a single injection in mice. The work does not yet speak to human biology, but it gestures toward a future in which the tools for protecting the heart are more varied, more precise, and perhaps more forgiving than those we have long re